prpf38a Antibody

What is PRPF38A and why is it important in cellular research?

PRPF38A (Pre-mRNA-splicing factor 38A) is a crucial component of the spliceosome complex that plays a fundamental role in pre-mRNA splicing and RNA processing mechanisms . As a key player in ensuring correct splicing of pre-mRNA molecules, PRPF38A dysfunction has been linked to various pathological conditions, including neurological disorders and several cancer types . The protein is particularly valuable for researchers investigating fundamental RNA processing mechanisms and disease pathways involving splicing dysregulation.

The importance of PRPF38A in cellular research lies in its central role in the spliceosome, which is responsible for removing introns from pre-mRNA. Researchers studying alternative splicing regulation, spliceosome assembly, or RNA processing disorders frequently target this protein to understand both normal cellular functions and disease mechanisms. The molecular weight discrepancy between observed (72 kDa) and calculated (37.5 kDa) values suggests potential post-translational modifications that may be functionally significant .

Which applications are suitable for PRPF38A antibody detection?

PRPF38A antibodies have been validated for multiple research applications, with optimization parameters outlined below:

For optimal results, researchers should perform antibody titration within these recommended ranges for their specific experimental system . The antibody demonstrates reactivity with both human and mouse PRPF38A, making it suitable for comparative studies across these species. When selecting application methods, consider that Western blotting provides quantitative information about protein expression levels, while immunostaining techniques (IHC/IF/ICC) deliver spatial information about subcellular localization.

How should PRPF38A antibodies be stored and handled to maintain activity?

Proper storage and handling of PRPF38A antibodies are critical for maintaining reactivity and specificity. The antibody should be stored at -20°C for long-term preservation (up to one year) . For frequent use, short-term storage at 4°C (up to one month) is acceptable to minimize freeze-thaw cycles that can degrade antibody quality .

The antibody is typically provided in a stabilizing buffer containing PBS with 50% glycerol, 0.5% BSA, and 0.02% sodium azide . This formulation helps maintain antibody integrity during storage. When handling the antibody:

• Avoid repeated freeze-thaw cycles by aliquoting the antibody into smaller volumes upon receipt

• Thaw completely at room temperature before use and mix gently by inversion or light vortexing

• Centrifuge briefly before opening to collect liquid at the bottom of the tube

• Handle using clean pipette tips to prevent contamination

• Return to appropriate storage temperature immediately after use

Researchers should note that sodium azide in the storage buffer is toxic and incompatible with horseradish peroxidase, which may interfere with certain detection systems. When using for applications involving HRP, ensure adequate washing steps to remove residual sodium azide .

How can researchers address the molecular weight discrepancy between predicted and observed PRPF38A size?

The notable discrepancy between the calculated molecular weight of PRPF38A (37.5 kDa) and its observed electrophoretic mobility (72 kDa) represents a common challenge in PRPF38A research . This difference requires careful experimental design and interpretation. Several methodological approaches can help researchers address this issue:

• Validation with multiple antibodies: Use antibodies targeting different epitopes of PRPF38A to confirm specificity of the observed band.

• Positive and negative controls: Include recombinant PRPF38A protein as a positive control and samples from PRPF38A-knockout or knockdown models as negative controls.

• Post-translational modification analysis: Investigate potential modifications through:

  • Phosphatase treatment to remove phosphorylation

  • Deglycosylation enzymes to remove glycosylation

  • Mass spectrometry analysis to identify modifications

• Alternative splicing investigation: Use RT-PCR with primers spanning different exons to identify potential splice variants.

• Denaturing conditions optimization: Test various reducing agents and denaturation temperatures to ensure complete protein unfolding.

When publishing results, researchers should clearly acknowledge this molecular weight discrepancy and provide details about validation methods used to confirm antibody specificity . This observation actually presents an interesting research question about potential post-translational regulation of PRPF38A function.

What are the optimal conditions for using PRPF38A antibodies in co-immunoprecipitation experiments?

Co-immunoprecipitation (Co-IP) represents a valuable approach for studying PRPF38A interactions within the spliceosome complex, though this application is not explicitly listed among the guaranteed applications for commercial antibodies . Researchers can optimize Co-IP protocols for PRPF38A studies with the following methodological considerations:

• Antibody selection: Choose antibodies raised against epitopes unlikely to be masked by protein-protein interactions. The antibody targeting the internal region (amino acids 104-153) may be suitable if this region is accessible in native protein complexes .

• Lysis buffer optimization:

  • Start with a mild non-denaturing buffer (e.g., 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol)

  • Include protease and phosphatase inhibitors to preserve protein integrity

  • For nuclear proteins like PRPF38A, consider specialized nuclear extraction protocols

• Binding conditions:

  • Use 2-5 μg antibody per 500 μg of protein lysate

  • Incubate overnight at 4°C with gentle rotation

  • Use protein A/G magnetic beads for capture (typically 25-50 μl of bead slurry)

• Washing stringency balance:

  • Include 3-5 wash steps with increasing stringency

  • Final washes should contain minimal detergent to reduce background while preserving specific interactions

• Elution and detection:

  • Elute with sample buffer containing SDS and DTT at 70°C (not boiling) to minimize IgG contamination

  • Validate results with reciprocal Co-IP using antibodies against suspected interaction partners

When analyzing spliceosome complex interactions, researchers should consider that these interactions may be RNA-dependent. Including RNase treatment controls can help distinguish direct protein-protein interactions from RNA-mediated associations.

How can researchers effectively use PRPF38A antibodies in multiple labeling immunofluorescence experiments?

Multiple labeling immunofluorescence is particularly valuable for studying PRPF38A within nuclear speckles and its colocalization with other spliceosome components. Successful implementation requires careful experimental design:

• Antibody compatibility planning:

  • Ensure primary antibodies originate from different host species (PRPF38A antibodies are typically rabbit-derived )

  • Select secondary antibodies with minimal cross-reactivity and spectrally separable fluorophores

  • Consider using directly conjugated primary antibodies for complex multi-labeling

• Sequential staining protocol:

  • Fix cells with 4% paraformaldehyde (10-15 minutes at room temperature)

  • Permeabilize with 0.1-0.3% Triton X-100 (10 minutes)

  • Block with 5% normal serum (from host of secondary antibody)

  • Apply PRPF38A antibody at 1:50-1:200 dilution

  • Wash thoroughly (3x PBS-T)

  • Apply other primary antibodies (either simultaneously if from different hosts or sequentially)

  • Add appropriate secondary antibodies

  • Counterstain nucleus with DAPI

• Controls for multi-labeling experiments:

  • Single primary antibody controls to evaluate bleed-through

  • Secondary-only controls to assess non-specific binding

  • Absorption controls using blocking peptides

• Advanced imaging considerations:

  • Use confocal microscopy for precise colocalization studies

  • Implement deconvolution algorithms to improve signal-to-noise ratio

  • Consider super-resolution techniques for detailed spliceosome structure analysis

Using this approach, researchers can effectively investigate PRPF38A interactions with other splicing factors like SR proteins, U1 snRNP components, or other spliceosome-associated proteins, providing valuable insights into functional relationships within these complexes.

What are common issues with PRPF38A antibody specificity and how can they be addressed?

Antibody specificity concerns represent a significant challenge in PRPF38A research. Researchers can implement several validation strategies to ensure reliable results:

• Validating antibody specificity:

  • Genetic approaches: Compare staining between wild-type and PRPF38A-knockout/knockdown samples

  • Immunizing peptide blocking: Pre-incubate antibody with excess immunizing peptide before application

  • Multiple antibody validation: Use antibodies targeting different epitopes and compare staining patterns

  • Recombinant protein controls: Include purified recombinant PRPF38A as a positive control

• Addressing common cross-reactivity issues:

  • Increase blocking strength (5-10% normal serum or BSA)

  • Optimize primary antibody concentration (perform titration experiments)

  • Increase washing duration and number of washes

  • Consider pre-adsorption of antibody with tissue/cell lysates from species not being studied

• Application-specific optimization:

  • For Western blotting: Test different blocking agents (milk vs. BSA) as milk may contain phosphoproteins that interfere with phospho-specific antibodies

  • For IHC/ICC: Compare different fixation methods and antigen retrieval protocols

  • For IF: Adjust detergent concentration during permeabilization

The discrepancy between predicted and observed molecular weights of PRPF38A (37.5 kDa vs. 72 kDa) increases the importance of proper controls to confirm specificity. When troubleshooting, systematically modify one variable at a time and maintain detailed records of protocol modifications and outcomes.

How should researchers design experiments to study PRPF38A expression in disease models?

When investigating PRPF38A's role in disease pathogenesis, particularly in neurological disorders and cancer where splicing dysregulation is implicated , researchers should implement robust experimental designs:

• Experimental design considerations:

  • Use multiple detection methods (qRT-PCR, Western blot, IHC) to correlate mRNA and protein levels

  • Include time-course analyses to capture dynamic changes in expression

  • Analyze both total protein expression and subcellular localization changes

  • Compare results across multiple cell lines or tissue types to identify cell-specific effects

• Disease model selection strategies:

  • Cell culture models: Compare normal cell lines with disease-relevant lines

  • Patient-derived samples: Analyze PRPF38A expression in affected vs. unaffected tissues

  • Animal models: Consider CRISPR-modified models with PRPF38A mutations

  • Use activation plasmids to upregulate PRPF38A expression and assess phenotypic consequences

• Analysis framework for PRPF38A expression:

  Disease Context	Recommended Analysis	Technical Considerations
  Cancer	Compare tumor vs. adjacent normal tissue	Account for tumor heterogeneity
  Neurological disorders	Analyze brain region-specific changes	Consider cell-type specific effects
  Splicing-related diseases	Correlate with alternative splicing events	Pair with RNA-seq analysis
  Treatment response	Monitor changes during therapy	Include time-matched controls

• Functional validation approaches:

  • Manipulate PRPF38A expression using CRISPR activation or RNAi knockdown

  • Assess effects on splicing using exon-junction microarrays or RNA-seq

  • Evaluate phenotypic consequences in disease-relevant assays

For all disease-related studies, researchers should carefully document patient/sample characteristics and ensure appropriate informed consent and ethical approvals are in place when using human specimens.

What are the best practices for quantifying PRPF38A protein levels in Western blot experiments?

Accurate quantification of PRPF38A by Western blotting requires careful attention to methodology and appropriate controls:

• Sample preparation optimization:

  • For nuclear proteins like PRPF38A, use specialized nuclear extraction protocols

  • Include protease inhibitors to prevent degradation

  • Standardize protein concentration through BCA or Bradford assays

  • Use loading controls appropriate for nuclear proteins (e.g., Lamin B1, HDAC1)

• Electrophoresis and transfer considerations:

  • Use gradient gels (4-12% or 4-15%) to resolve the 72 kDa observed band efficiently

  • Optimize transfer conditions for higher molecular weight proteins

  • Consider wet transfer methods for more quantitative results

  • Validate transfer efficiency with reversible protein stains

• Antibody incubation parameters:

  • Determine optimal antibody concentration (1:500-1:2000)

  • Incubate primary antibody overnight at 4°C for improved signal-to-noise ratio

  • Use validated secondary antibodies at appropriate dilutions

  • Consider fluorescent detection methods for wider dynamic range

• Quantification methodology:

  • Use digital image acquisition with linear dynamic range

  • Avoid saturated signals that prevent accurate quantification

  • Normalize to appropriate loading controls

  • Perform technical replicates (minimum of three)

  • Include standard curves of recombinant protein for absolute quantification

• Data analysis best practices:

  • Report relative rather than absolute densitometry values

  • Apply statistical analysis appropriate for sample size

  • Present both representative images and quantification graphs

  • Include all technical details in methods section for reproducibility

Researchers should be particularly aware of the molecular weight discrepancy for PRPF38A and consistently report which band was quantified. For studies comparing PRPF38A levels across different conditions, all samples should be processed in parallel and analyzed on the same blot when possible to minimize technical variation.

How can PRPF38A antibodies be used to investigate spliceosome dynamics and assembly?

PRPF38A antibodies offer valuable tools for studying spliceosome dynamics through several advanced methodological approaches:

• Chromatin Immunoprecipitation (ChIP) applications:

  • Optimize crosslinking conditions (1% formaldehyde for 10 minutes is standard)

  • Use sonication parameters that generate 200-500 bp fragments

  • Employ PRPF38A antibodies at 2-5 μg per ChIP reaction

  • Analyze association with actively transcribed genes

  • Combine with RNA polymerase II ChIP to correlate with transcriptional activity

• RNA Immunoprecipitation (RIP) protocols:

  • Use mild crosslinking (0.1-0.3% formaldehyde)

  • Include RNase inhibitors in all buffers

  • Sequence associated RNAs to identify preferred PRPF38A binding substrates

  • Compare binding patterns across different cellular conditions

• Proximity ligation assay (PLA) for protein interactions:

  • Combine PRPF38A antibody with antibodies against other spliceosome components

  • Optimize probe concentration and incubation times

  • Use confocal microscopy for precise signal localization

  • Quantify interaction signals across different cell states or treatments

• Live-cell imaging applications:

  • Correlate antibody staining patterns with fluorescently tagged PRPF38A

  • Validate localization patterns using antibodies against different epitopes

  • Use as validation for CRISPR-mediated tagging of endogenous PRPF38A

These methods can reveal dynamic changes in PRPF38A associations during spliceosome assembly, activation, and recycling. Researchers can investigate how these dynamics are altered in response to transcriptional inhibition, splicing modulation, or disease-relevant mutations.

What considerations are important when using PRPF38A antibodies for tissue microarray (TMA) analysis?

Tissue microarray analysis using PRPF38A antibodies requires specific optimization strategies to achieve consistent and interpretable results:

• TMA-specific protocol adaptations:

  • Optimize antigen retrieval methods (test both heat-induced and enzymatic methods)

  • Determine ideal antibody dilution (starting at 1:100-1:300)

  • Include positive control tissues with known PRPF38A expression

  • Incorporate negative controls (primary antibody omission and isotype controls)

• Staining pattern interpretation guidelines:

  • Document both nuclear and potential extranuclear staining

  • Use semi-quantitative scoring systems (0-3+ intensity scale)

  • Consider automated image analysis for objective quantification

  • Evaluate percentage of positive cells and staining intensity separately

• Validation approaches for TMA results:

  • Confirm key findings on whole tissue sections

  • Correlate with mRNA expression data when available

  • Validate observations across independent TMAs

  • Consider cellular context and tissue heterogeneity in interpretation

• Data analysis frameworks:

  • Use appropriate statistical methods for TMA scoring data

  • Account for missing data points in TMAs

  • Consider correction for multiple hypothesis testing

  • Correlate PRPF38A expression with clinical parameters and outcomes

Researchers should recognize that nuclear proteins like PRPF38A may show variable staining based on fixation time, processing methods, and storage duration of tissues. Standardizing these parameters across the TMA is crucial for generating comparable results.

How can researchers effectively combine PRPF38A protein analysis with RNA splicing assessment?

Integrating PRPF38A protein analysis with splicing outcome assessment provides comprehensive insights into structure-function relationships. Researchers can implement several methodological approaches:

• Integrated experimental design strategies:

  • Perform parallel analysis of PRPF38A protein levels/localization and splicing patterns

  • Design experiments with coordinated sample collection for protein and RNA analysis

  • Include time-course studies to capture dynamic relationships

  • Manipulate PRPF38A levels using CRISPR activation or RNAi and assess splicing consequences

• Splicing assessment technologies:

  • RT-PCR for targeted splicing event analysis

  • RNA-seq with computational tools optimized for alternative splicing detection

  • Exon-junction microarrays for genome-wide splicing profiling

  • Minigene splicing reporters for mechanistic studies

• Correlation analysis framework:

  • Quantify PRPF38A levels by Western blot using recommended dilutions (1:500-1:2000)

  • Normalize splicing changes to gene expression levels

  • Use statistical approaches appropriate for multidimensional data

  • Consider machine learning approaches for complex pattern identification

• Visualization and validation strategies:

  • Combine RNA FISH for specific transcripts with PRPF38A immunofluorescence

  • Use high-content imaging to correlate nuclear PRPF38A distribution with splicing outcomes

  • Implement biochemical fractionation to correlate active vs. inactive PRPF38A pools with splicing activity

This integrated approach allows researchers to establish whether changes in PRPF38A expression, localization, or post-translational modification directly impact specific splicing events, providing mechanistic insights into both normal cellular function and disease-related dysregulation.

How can PRPF38A antibodies be utilized in single-cell analysis technologies?

The application of PRPF38A antibodies in single-cell analysis represents an emerging frontier in splicing research, allowing investigation of cell-to-cell heterogeneity in splicing regulation:

• Single-cell immunofluorescence optimization:

  • Use high-sensitivity detection systems (e.g., tyramide signal amplification)

  • Implement automated image acquisition for statistical power

  • Optimize antibody concentration (typically higher than bulk analysis)

  • Include careful controls for background and specificity

• Mass cytometry (CyTOF) applications:

  • Conjugate PRPF38A antibodies with rare earth metals

  • Validate signal specificity using positive and negative controls

  • Combine with markers for cell cycle, differentiation status, and other splicing factors

  • Implement dimensionality reduction techniques for data analysis

• Spatial transcriptomics integration:

  • Correlate spatial PRPF38A protein patterns with local transcriptome profiles

  • Use sequential IF and in situ RNA analysis on the same samples

  • Consider computational approaches to integrate protein and RNA data

  • Analyze tissue regions with varying PRPF38A expression for splicing differences

• Methodological considerations:

  • Increase sample size to account for cell-to-cell variability

  • Implement rigorous statistical approaches appropriate for single-cell data

  • Consider cellular context (cell cycle stage, differentiation status) in analysis

  • Validate findings with complementary single-cell approaches

These approaches allow researchers to investigate how heterogeneity in PRPF38A expression or localization within a seemingly homogeneous population might contribute to splicing regulation variability and potentially influence cell fate decisions or disease progression.

What are the considerations for using PRPF38A antibodies in studying post-translational modifications?

The significant discrepancy between calculated (37.5 kDa) and observed (72 kDa) molecular weights of PRPF38A suggests extensive post-translational modifications (PTMs) that may regulate its function. Investigating these PTMs requires specific methodological approaches:

• Phosphorylation analysis strategies:

  • Use phosphatase treatment to confirm phosphorylation contribution to mobility shift

  • Complement with phospho-specific antibodies if available

  • Consider phospho-proteomic mass spectrometry for site identification

  • Use kinase/phosphatase inhibitors to manipulate phosphorylation status

• Other PTM investigation approaches:

  • Test deglycosylation enzymes to assess potential glycosylation

  • Investigate SUMOylation through immunoprecipitation with SUMO antibodies

  • Assess ubiquitination status using ubiquitin-directed antibodies

  • Consider acetylation analysis for nuclear proteins

• PTM-specific sample preparation:

  • Include appropriate PTM inhibitors during lysis (phosphatase, deubiquitinase inhibitors)

  • Optimize lysis conditions to preserve labile modifications

  • Consider enrichment strategies for modified proteins

  • Use appropriate controls (treatment with modifying or demodifying enzymes)

• Functional correlation methods:

  • Correlate PTM status with PRPF38A localization using immunofluorescence

  • Assess impact of PTM-mimicking mutations on splicing function

  • Investigate cell cycle or stress-dependent changes in modification patterns

  • Evaluate disease-related alterations in PRPF38A PTM profile

Understanding PRPF38A PTMs may provide crucial insights into regulatory mechanisms controlling spliceosome assembly and function, potentially revealing new therapeutic targets for splicing-related diseases.

How can PRPF38A antibodies contribute to understanding therapy resistance mechanisms in cancer?

Dysregulation of splicing mechanisms has emerged as a potential contributor to therapy resistance in cancer, making PRPF38A an interesting target for investigation in this context:

• Experimental design for therapy resistance studies:

  • Compare PRPF38A expression/localization in sensitive vs. resistant cell models

  • Analyze changes in PRPF38A levels during acquisition of resistance

  • Correlate with alternative splicing changes in resistance-associated genes

  • Manipulate PRPF38A levels using CRISPR activation and assess impact on drug sensitivity

• Clinical sample analysis approach:

  • Use PRPF38A antibodies for IHC analysis of matched pre- and post-treatment samples

  • Optimize antibody dilution (1:100-1:300) for tissue analysis

  • Implement digital pathology for quantitative assessment

  • Correlate findings with treatment outcomes and progression-free survival

• Mechanistic investigation strategies:

  • Identify PRPF38A-dependent splicing events altered in resistant cells

  • Focus on cancer-relevant genes with therapy-related alternative splicing

  • Validate functional significance through targeted splicing manipulation

  • Assess potential for combinatorial approaches targeting PRPF38A-regulated pathways

• Translational research considerations:

  • Evaluate PRPF38A as a potential biomarker for treatment stratification

  • Investigate relationship with existing splicing inhibitors

  • Consider PRPF38A network as a source of novel therapeutic targets

  • Assess potential for synthetic lethality approaches

By applying PRPF38A antibodies in these research contexts, scientists can gain insights into how splicing regulation contributes to therapy resistance mechanisms and potentially identify new approaches to overcome resistance in cancer treatment.